Press Room

The Charcot-Marie-Tooth Association (CMTA) is excited to share that our Alliance Partner, NMD Pharma, has received clearance from the US Food and Drug Administration (FDA) to initiate a Phase II clinical trial for their investigational ...

The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth (CMT) disease research aimed at bringing treatments to patients, announced today an investment of $240K into a new gene replacement therapy for CMT4A, with a ...

Finding Your Gene Researchers have discovered over 120 genes linked to CMT; dozens were found with CMTA funding initiatives. Despite this, referred to as the “diagnostic gap,” more than 50% of all who have CMT Type ...

The 2024 CMTA Patient & Research Summit will take place on Friday, September 6th – Sunday, September 8th at the Denver Marriott West in Denver, Colorado. The CMTA Summit will offer life-improving presentations on living ...

The Charcot-Marie-Tooth Association (CMTA), the world’s largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research aimed at bringing treatments to patients and improving the lives of those living with Charcot-Marie-Tooth disease (CMT), is excited to announce ...